ClinicalTrials.gg
RecruitingNCT06346054MAGECUpdated Feb 17, 2026

Molecular Assessment for Gastro-Esophageal Cancer

An interventional study of Breath analysis and Blood analysis in Esophageal Cancer, Gastric Cancer and Barrett Esophagus, sponsored by KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by KU Leuven · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Non-randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Esophageal Neoplasms with a site in Belgium — 17 open to participants now, 22 under way, 5 of them phase 3. Esophageal Neoplasms · Belgium.

Planned enrollment
3rd of 32
1,000 · median 198
Started
2024
with 6 others
No phase
11 of 41
7 open now
Primary completion
2029-07
later than 17 of 21 live
Registered
36th of 41
by date
Lead sponsor
3 of 41
KU Leuven

Among the 41 studies in Esophageal Neoplasms with a site in Belgium, this one is the 3rd largest by planned enrollment of the 32 interventional ones that give a count, is one of 7 that started in 2024, is one of 11 with no phase, reaches primary completion later than 17 of the 21 other live ones, and was the 36th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

17 of the 41 studies in Esophageal Neoplasms with a site in Belgium are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Esophageal Neoplasms with a site in Belgium, or all of them as a file.
02

Study summary

The goal of this minimally invasive interventional study is to learn if oncometabolic biomarkers, detected in the exhaled breath and blood can identify early-stage gastro-oesophageal cancer in patient at risk for gastro-oesophageal cancer.

The main questions this study aims to answer:

Are oncometabolites proficient and reproducible enough to function as diagnostic biomarkers? Can these biomarkers identify early-stage gastro-esophageal cancer? Researchers will compare participants with gastro-oesophageal cancer to healthy controls and participants with Barrett's esophagus to detect meaningful differences between the groups.

Participants will provide a breath and blood sample during their routine standard of care visits.

03

Conditions studied

  • Esophageal Cancer
  • Gastric Cancer
  • Barrett Esophagus

Keywords

  • Oncometabolites
  • Early-stage cancer
  • Diagnostic testing
  • Screening
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary written of the participant or their legally authorized representative has been obtained prior to any breath or blood analysis
  2. >18 years old
  3. Barrett's esophagus or treatment naïve gastro-esophageal cancer stage I to IV
  4. Voluntary healthy controls

Exclusion criteria

Exclusion Criteria:

  1. \<18 years old
  2. Patient has history of:

    1. Active other cancer than gastro-esophageal cancer
    2. Prior cancer treated \<3 years ago
    3. Hepatic dysfunction/liver failure (MELT >7)
  3. Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the study plan.
  4. Insufficient/unreliable quality of breath (e.g., breath flow) or plasma sample (e.g., haemolytic sample)
  5. Incarcerated individuals
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    Gastro-esophageal cancer group

    Participants with gastroesophageal cancer providing a breath and blood sample for biomarker identification

    Diagnostic Test: Breath analysis · Diagnostic Test: Blood analysis

  • Active comparator
    Barrett's esophagus group

    Participants with Barrett's esophagus providing a breath and blood sample for biomarker identification

    Diagnostic Test: Breath analysis · Diagnostic Test: Blood analysis

  • Active comparator
    Healthy controls

    Healthy controls providing a breath and blood sample for biomarker identification

    Diagnostic Test: Breath analysis · Diagnostic Test: Blood analysis

Interventions

  • Diagnostic testBreath analysis

    Detection of proteins and volatile organic compounds (oncometabolites) in the exhaled breath

  • Diagnostic testBlood analysis

    Detection of proteins and circulating tumor DNA (oncometabolites) in the peripheral blood

06

What researchers measure

Primary outcomes

  1. Identification of the concentrations of oncometabolites

    Identify the concentrations of cancer-related metabolites (oncometabolites) in the exhaled breath and blood compared to healthy controls

    Time frame: year 1-2

Secondary outcomes

  1. Assessment of incidence of early-stage cancer

    Distinguish early-stage gastro-oesophageal cancer from Barrett's esophagus and healthy controls based on sensitivity, specificity and accuracy of the oncometabolite concentration

    Time frame: year 2-5

  2. Assessment of incidence of therapy response

    Predict and assess therapy response prior to surgery, based on sensitivity, specificity and accuracy of the oncometabolite concentration

    Time frame: year 2-5

  3. Assessment of percentage change of therapy response

    Assess changes in the concentrations of the oncometabolites related to treatment.

    Time frame: year 2-5

  4. Assessment of incidence of recurrence

    Predict and assess recurrence, based on sensitivity, specificity and accuracy of the oncometabolite concentration

    Time frame: year 2-5

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data will be shared upon reasonable request with the principal investigator.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jul 2029, 59 months after the start.

Of 209 non-industry interventional studies with no phase under Esophageal Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 94. This study's planned 59 months is above that.

Counting every sponsor, half of 218 studies reached it within 46 months; a quarter within 23 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2024
First posted
Apr 3, 2024
StartActual
Aug 1, 2024
Primary completionEst.
Jul 1, 2029
CompletionEst.
Jul 1, 2029
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06346054
Lead sponsor
KU Leuven
Responsible party
Stijn Vanstraelen (Principal investigator, Universitaire Ziekenhuizen KU Leuven) — Principal investigator
First posted
Apr 3, 2024
Start date
Aug 1, 2024
Primary completion
Jul 1, 2029 (estimated)
Completion
Jul 1, 2029 (estimated)
Last update
Feb 17, 2026

Study contacts

Stijn Vanstraelen, MD
Contact
stijn.vanstraelen@kuleuven.be
16347863 ext. 0032
Stijn Vanstraelen, MD
principal investigator · Universitaire Ziekenhuizen KU Leuven
Philippe Nafteux, MD, PhD
principal investigator · Universitaire Ziekenhuizen KU Leuven

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion